INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc.

Revenue $6,841,250, up 5% from $6,532,000; consolidated clinic revenue up 4% to $6.72M.
Net loss from continuing operations improved to $(5.3)M from $(7.7)M; adjusted EBITDA $(3.2)M vs $(2.2)M.
Raised $11.5M in gross proceeds from Dec 2025 and Jan 2026 financings; Series C-2 Preferred converted/retired.
Acquired Indiana-based Family Beginnings in Feb 2026; it had $1.2M revenue and $0.2M net income TTM Sep 2025.
Patent issued for modified INVOcell device extending protection through 2040; total common shares ~1.8M as of June 2, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INVO Fertility, Inc. reported fiscal year 2025 results: revenue $6,841,250, net income $(5.3) million.

Period: fiscal year 2025
Revenue: $6,841,250
Net income: $(5.3) million
Result: reported results

Exact text from the filing

and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including

View on SEC.gov

Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-026777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.